Cellerant Therapeutics
US-based Cellerant Therapeutics innovates cell and antibody-based immunotherapies at clinical stage.
Founded
2003US-based Cellerant Therapeutics innovates cell and antibody-based immunotherapies at clinical stage.
Founded in San Carlos, United States, Cellerant Therapeutics is a clinical-stage company dedicated to developing innovative cell- and antibody-based immunotherapies. The company's core mission is to advance the treatment of hematologic malignancies and other blood-related disorders through pioneering therapeutic approaches. Cellerant's product pipeline includes cell-based therapies aimed at treating acute myeloid leukemia (AML) and other cancers, focusing on unmet medical needs in the oncology market.
Cellerant Therapeutics has attracted notable investors and affiliations, including partnerships with leading research institutions and biotech firms. The company has achieved significant milestones, such as advancing its lead product candidates into clinical trials and receiving regulatory designations that expedite development. Overall, Cellerant's impact lies in its potential to transform cancer treatment paradigms and improve patient outcomes through cutting-edge immunotherapy solutions.
Companies similar to Cellerant Therapeutics include Celldex Therapeutics, CERo Therapeutics, Lyell Immunopharma and Cello Therapeutics.
Cellerant Therapeutics was founded in 2003.
Cellerant Therapeutics' headquarters is located in San Carlos, CA, US.
Cellerant Therapeutics' most recent funding round was for $1.5M (USD) in September 2016.
As of Sep 26, 2016, Cellerant Therapeutics has disclosed funding of $109.8M (USD). Undisclosed round amounts are excluded.
Cellerant Therapeutics has 101 employees as of Feb 5, 2024.
Cello Therapeutics
cellothera.com
